# ZENTALIS PHARMACEUTICALS INC (ZNTL)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ZNTL/

- Reporting holders: 3
- Reported value: $30.5K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [DLK Investment Management, LLC](https://holderbook.com/funds/2016793-dlk-investment-management-llc/) | $29.8K | 10,750 | 0.0% | 1 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $568 | 205 | 0.0% | 1 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $152 | 55 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $30.5K |
| Q2 2026 | 116 | $249.2M |
| Q1 2026 | 101 | $102.8M |
| Q4 2025 | 86 | $55.1M |
| Q3 2025 | 100 | $81.7M |
| Q2 2025 | 116 | $64.6M |
| Q1 2025 | 131 | $93.4M |
| Q4 2024 | 142 | $195.8M |
| Q3 2024 | 135 | $264.1M |
| Q2 2024 | 143 | $316.0M |
| Q1 2024 | 142 | $1.4B |
| Q4 2023 | 120 | $1.3B |